Cytotoxicity of mebendazole against established cell lines from the human, rat, and mouse liver
- 54 Downloads
The direct cytotoxicity of mebendazole (MBZ) was investigated by using cell lines derived from human, mouse and rat liver. It was demonstrated that Chang liver cells (derived from human liver) were more sensitive to the cytotoxic effects of MBZ than the other two cell lines. Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25–0.50 mg/l in a 42-h culture). Inhibition of the proliferation of Chang liver cells by MBZ was detected at a concentration of 0.008 mg/l, a lower concentration than that having a cytotoxic effect. The other two cell lines were less sensitive to the inhibitory effect of MBZ. Proliferation of human mononuclear cells following stimulation by phytohemagglutinin (PHA) was inhibited by MBZ, and this inhibition was more extensive than that of cells stimulated with whole formalin-treatedPseudomonas aeruginosa. It is suggested that dividing cells may be more sensitive to MBZ cytotoxicity. This anti-proliferative effect may be related to its clinically known side effects, such as hepatotoxicity and bone marrow suppression.
Key wordsMebendazole Cytotoxicity Cell lines In vitro
Unable to display preview. Download preview PDF.
- Grove DI (1989) Treatment. In: Grove DI ed. Strongyloidiasis: a major roundworm infection of man. Taylor & Francis, London, pp 199–231Google Scholar
- Harris A (1979) Pyrexia and mebendazole. BMJ 2: 1365Google Scholar
- Horstmann RD, Kern P, Volkmert KJ, Dietrich M (1982) Observations on mebendazole vs. thiabendazole in the treatment of human trichinellosis. Tropenmed Parasit 33: 191–194Google Scholar
- Libova E, Mittermayer T, Bayer A, Chroust K, Sucharova T, Chudora M (1984) Epidemy of human trichinellosis in Bordejov region in 1980. Helminthologia 21: 81–91Google Scholar
- Murray-Lyon IM, Reynolds KW (1979) Complications of mebendazole treatment for hydatid disease. BMJ 2: 1111–1112Google Scholar
- Shikiya K, Kuniyoshi T, Higashionna A, Arakaki T, Oyakawa T, Kadena K, Kinjo F, Saito A, Asato R (1990) Treatment of strongyloidiasis with mebendazole and its combination with thiabendazole. J Jpn Assoc Infect Dis 64: 1408–1415 (English abstract)Google Scholar
- Van den Bossche H (1972) Biochemical effects of the anthelmintic drug mebendazole. In: Van den Bossche H (ed) Comparative biochemistry of parasites. Academic Press, New York and London, pp 139–157Google Scholar